A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Based on preclinical data implicating GR, AR, and JAK/STAT activation as potent mechanisms of
breast cancer cell survival despite chemotherapy administration (i.e. chemotherapy
resistance), the study will test a novel approach for improving chemotherapy effectiveness by
adding Hsp90 inhibition to antagonize the anti-apoptotic signaling pathways that are
initiated via GR, AR, and JAK/STAT activation.